EP3819308A1 — Process for the manufacture of derivatized amino acids
Assigned to Fresenius Kabi Ipsum SRL · Expires 2021-05-12 · 5y expired
What this patent protects
The present invention relates to peptide synthesis, and in particular to a process for the manufacture of protected amino acids substituted at their side-chains. In addition, the present invention relates to the use of such protected amino acids in the preparation of GLP-1 analog…
USPTO Abstract
The present invention relates to peptide synthesis, and in particular to a process for the manufacture of protected amino acids substituted at their side-chains. In addition, the present invention relates to the use of such protected amino acids in the preparation of GLP-1 analogues, such as for instance liraglutide and semaglutide.
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.